SPOTLIGHT: Lilly loses bid to stop drug-reselling

A European court has ruled that Eli Lilly can't block a U.K. pharmacy from buying its meds in Turkey at cheaper prices and reselling them in the United States. Report

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.